AzTrials
AzTrials

MelanomaPhase 2SPOTLIGHT203NCT04570332

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

A Phase 2 study testing BO-112 plus pembrolizumab and Tissue Biopsies in people with Melanoma, run by Highlight Therapeutics at 19 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Melanoma
What is being tested?
BO-112 plus pembrolizumab and Tissue Biopsies
Could I receive a placebo?
No, everyone receives an active treatment
How many people
42 participants
Where
19 sitesin 2 countries
Study dates
30 Dec 2020to 4 Nov 2024
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Be willing and able to give written informed consent for the study.
  • Be ≥ 18 years of age on day of informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically or cytologically confirmed diagnosis of cutaneous or mucosal melanoma.
  • Known BRAF status.
  • Have unresectable stage III or stage IV melanoma. Patients must have progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb) administered as monotherapy, or in combination with other checkpoint inhibitors or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria:
Show all 33Show fewer
  • Received at least 6 weeks of standard dosing of an approved anti-PD-1/L1 mAb.
  • Demonstrated disease progression (PD) on or after PD-1/L1 as defined by RECIST v1.1. The initial evidence of PD is to be confirmed by a second assessment no less than four weeks from the date of the first documented PD, in the absence of rapid clinical progression.
  • Progressive disease documented within 12 weeks from the last dose of anti-PD-1/L1 mAb.
  • This determination is made by the investigator. Once PD is confirmed, the initial date of PD documentation will be considered the date of disease progression.
  • Anti-PD-1-based therapy should have been the last line of systemic therapy as part of first line treatment. Prior treatment either in neo or adjuvant setting is allowed (if patient did not develop progressive disease while on receiving it). In the case of patients who develop progressive disease during adjuvant therapy, that treatment will be counted as one prior line, and will be eligible if only that prior line has been administered.
  • At least one tumoral lesion that is RECIST 1.1 measurable and amenable for IT injection.
  • At least one accessible tumor lesion that is amenable to weekly injection. If liver is a site of injection, presence of at least one additional tumor lesion outside the liver amenable for injection.
  • Willingness to provide biological samples required for the duration of the study including a fresh tumor biopsy sample. NOTE: If possible, the biopsied lesion should be a non-target lesion.
  • Adequate hematologic and organ function defined by the following laboratory results obtained within 2 weeks prior to the first dose of study treatment:
  • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
  • Platelet count ≥ 100 x 10^9/L
  • Hemoglobin (Hgb) ≥ 9 g/dL
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x upper limit of normal (ULN) (5 × ULN if presence of liver metastases)
  • Serum total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN
  • Prothrombin time (PT) (or international normalized ratio [INR]) within normal limits and activated partial prothrombin time (aPTT) within normal limits
  • Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 30 mL/min (calculated per institutional standard)
  • Female patient of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the injection of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Female patients who are not pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment.
  • Female patients of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity from the beginning of the study through 120 days after receiving the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
  • Non-pregnant, non-breast-feeding women may be enrolled if they are willing to use 2 methods of birth control or are considered highly unlikely to conceive. Highly unlikely to conceive is defined as 1) surgically sterilized, or 2) postmenopausal (a woman who is ≥45 years of age and has not had menses for greater than 1 year will be considered postmenopausal), or 3) not heterosexually active for the duration of the study. The two birth control methods can be either: two barrier methods or a barrier method plus a hormonal method to prevent pregnancy.
  • Patients should be informed that taking the study medication may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study. In order to participate in the study, they must adhere to the contraception requirement (described above). If there is any question that a patient will not reliably comply with the requirements for contraception, that patient should not be entered into the study.
  • Male patients should agree to use an adequate method of contraception from the beginning of the study through 120 days after receiving the study medication.
  • In countries where human immunodeficiency virus (HIV) positive patients can be included, HIV infected participants must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease defined as:
  • Participants on ART must have a CD4+ T-cell count >350 cells/mm3 at time of screening;
  • Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening;
  • Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to study entry (Day 1).
  • Able and willing to comply with study and follow-up procedures.

Who cannot join

  • Uveal melanoma.
  • Prior grade 3-4 irAE due to immune checkpoint inhibitors requiring systemic steroids for more than 2 weeks.
  • Prior intra-tumoral treatments.
  • If a liver lesion is the site of injection:
  • macroscopic tumor infiltration by the lesion to be injected into the main portal vein, hepatic vein or vena cava;
  • portal vein thrombosis;
Show all 30Show fewer
  • prior embolization of liver lesions;
  • radiofrequency, cryotherapy or microwave ablation in the last 6 months;
  • Child-Pugh B or C;
  • All AST, ALT and bilirubin greater than >2.5 ULN.
  • Contraindications to tumor biopsy and injections of the metastasis(es), such as coagulopathy, therapeutic dose anticoagulant treatment and treatment with long-acting agents such as clopidogrel which cannot be safely stopped.
  • Chemotherapy or biological cancer therapy within 4 weeks prior to the first dose of study treatment. Note: Participants must have recovered from all adverse events (AEs) due to previous therapies to ≤ Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy may be eligible.
  • Palliative radiotherapy within 1 week of start of study treatment. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
  • Clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
  • History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
  • Allergy to BO-112 and/or any of its excipients.
  • Allergy to pembrolizumab and/or any of its excipients.
  • Active infection requiring systemic therapy.
  • History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
  • Active autoimmune disease that required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
  • Receiving systemic immunosuppressive therapy within 28 days before enrolment with the exceptions of intranasal, topical, and inhaled corticosteroids or oral corticosteroids at physiological doses not exceeding 10 mg/day of prednisone or equivalent.
  • HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
  • Known history of hepatitis B (defined as HbsAg reactive) or known active hepatitis C (defined as HCV RNA [qualitative] detected) virus infection. Patients who are hepatitis B surface antigen negative and HBV viral DNA negative are eligible.
  • Patients who had HBV but have received an antiviral treatment and show non-detectable viral DNA for 6 months are eligible.
  • Patients who are seropositive because of HBV vaccine are eligible.
  • Patients who had HCV but have received an antiviral treatment and show no detectable HCV viral DNA for 6 months are eligible.
  • Has received a live vaccine within 28 days prior to the first dose of study drug. For COVID vaccines a 72 hour wash out period is necessary.
  • History of allogenic tissue or solid organ transplant.
  • Is currently participating or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment (patients who are in a follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent).
  • Any clinically significant psychiatric, social, or medical condition that, in the opinion of the Investigator, could increase patient's risk, interfere with protocol adherence, or affect a patient's ability to give informed consent.

Trial locations and contacts

19 sites in 2 countries.

19 sites in 2 countries

Spain12 sites

  • H. Universitari Germans Trias i Pujol

    Badalona, Barcelona

  • H. Universitari Quirón Dexeus

    Barcelona

  • Hospital Clinic de Barcelona

    Barcelona

  • Hospital Clara Campal - HM Sanchinarro

    Madrid

  • Hospital General Universitario Gregorio Marañón

    Madrid

  • Hospital Universitario 12 de Octubre

    Madrid

  • MD Anderson Cancer Center

    Madrid

  • Hospital Clínico Universitario Virgen de la Arrixaca

    Murcia

  • Clínica Universidad de Navarra

    Pamplona

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, Tenerife

  • Hospital Universitario Virgen Macarena

    Seville

  • H. General Universitario de Valencia

    Valencia

Other trials in Spain

France7 sites

  • Centre Hospitalier Universitaire de Bordeaux

    Bordeaux

  • Centre Hospitalier Universitaire de Grenoble

    Grenoble

  • Hopital Lyon Sud

    Lyon

  • Centre Hospitalier Universitaire de Nantes

    Nantes

  • Centre Hospitalier Universitaire de Nice

    Nice

  • Hôpital Ambroise-Paré

    Paris

  • Institut Gustave Roussy

    Paris

Other trials in France

About this study

Official title: Phase 2 Single Arm Clinical Study to Evaluate the Efficacy and Safety of Intratumoral Administration of BO-112 in Combination With Pembrolizumab in Subjects That Have Progressed on Anti-PD-1-based Therapy for Stage III or IV Melanoma

This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma that have progressed on anti-PD-1-containing treatment.

Read the detailed description

Patients with advanced Stage III/IV melanoma, refractory or resistant to anti-PD-1 treatment, were treated with the combination of intra-tumoral (IT) BO-112 and Q3W IV pembrolizumab. IT administration of BO-112 was performed once weekly (QW) for the first 7 weeks and then once every three weeks (Q3W).

The primary and secondary endpoints include overall response rate (ORR), durability of response (DOR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and safety profile.

Conditions
Melanoma
Being tested
BO-112 plus pembrolizumab, Tissue Biopsies
Keywords
BO112, Intratumoral, Immunotherapy, TLR3, Melanoma
Medical subject headings
Melanoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BO-112 plus pembrolizumabDrug

    Also called KEYTRUDA®

    Patients will be treated with the combination of BO-112 and pembrolizumab. Order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles

  • Tissue BiopsiesProcedure or surgery

    Pre and post (if feasible) treatment tumor tissue biopsies will be used for correlative research.

Study groups in NCT04570332
Study groupRoleWhat they receive
Single ArmExperimentalPatients will be treated with a combination of IT BO-112 and IV pembrolizumab.BO-112 will be administered once weekly (QW) for the first 7 weeks and then once every three weeks (Q3W); pembrolizumab Q3W will be administered IV. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions.
Receives: Drug: BO-112 plus pembrolizumab; Procedure: Tissue Biopsies

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Response Rate

    Percentage of patients achieving a complete response (CR) or partial response (PR) as best overall response, by independent radiological central review (IRCR) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Measured: From the first dose of study treatment to the date of CR or PR assessed up to 2 years

Secondary outcomes (5)

  1. Number of Participants With Adverse Events and Serious Adverse Events

    The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), v5.0 was used for grading toxicities.

    Measured: 2 years and 9 months

  2. Disease Control Rate

    Participants with complete response (CR), or partial response (PR), or stable disease (SD) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR) and modified RECIST 1.1 for immune-based therapeutics (iRECIST)

    Measured: From the first dose of study treatment to the date of best response (i.e. CR, PR, or SD) on study up to 2 years

  3. Duration of Response

    Median DOR (CR or PR) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR) by IRCR

    Measured: From the date of CR or PR until the date of event or censoring up to 2 years

  4. Progression Free Survival

    Progressive disease (PD) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR) by IRCR or death

    Measured: From the first dose of study treatment to the date of radiologic progression or death, whichever comes first, up to 2 years

  5. Overall Survival

    Median overall survival for all patients treated with at least one dose of the study drug

    Measured: From the first dose of study treatment to death from any cause up to 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Sep 2020
  2. Study start30 Dec 2020
  3. Primary completion3 Oct 2023
  4. Study completion4 Nov 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
This is a phase 2 study with one single treatment arm (BO-112 in combination with pembrolizumab)
Masking
None (open label)
Enrolment
42 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04570332
Sponsor's protocol ID
BOT112-03
Other IDs
2020-003921-51, KEYNOTE-B77 / MK-3475-B77
Acronym
SPOTLIGHT203
Status last verified
Nov 2025
First submitted
22 Sep 2020
Last updated
26 Nov 2025
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Marquez-Rodas I, Dutriaux C, Saiag P, de la Cruz Merino L, Castanon Alvarez E, Robert C, Rodriguez-Moreno JF, Arance A, Cerezuela-Fuentes P, Montaudie H, Sanmamed MF, Gonzalez-Cao M, Charles J, Lopez Criado MP, Berrocal A, de Miguel E, Funck-Brentano E, Prey S, Alamo de la Gala MC, Melero I, Aviles-Izquierdo JA, Roman R, Garcia-Pelaez B, Rodriguez S, Trnkova ZJ, Quintero M, Macia S, Chaney MF, Dalle S. BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. J Clin Oncol. 2025 Sep;43(25):2806-2815. doi: 10.1200/JCO-24-02595. Epub 2025 Jun 27.

    PubMed 40577656

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing BO-112 plus pembrolizumab and Tissue Biopsies in people with Melanoma, run by Highlight Therapeutics at 19 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 33 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 19 sites in Spain, France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 26 Nov 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Response Rate (time frame: From the first dose of study treatment to the date of CR or PR assessed up to 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04570332, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in